Triple combination therapies for anti-aging
AssigneeLunella Biotech, Inc.
InventorsMichael P. LISANTI, Federica SOTGIA
Life of this patent
Estimating the term…
Abstract
The present approach effectively eradicates senescent cells and cells carrying the hallmarks associated with aging, through inhibiting mitochondrial biogenesis during induced mitochondrial oxidative stress, without inhibiting normal cells. Embodiments may include a therapeutic agent that inhibits mitochondrial biogenesis and targets the large mitochondrial ribosome, a therapeutic agent that inhibits mitochondrial biogenesis and targets the small mitochondrial ribosome, and a therapeutic agent that behaves as a pro-oxidant or induces mitochondrial oxidative stress. Some embodiments include sub-antimicrobial antibiotic concentrations, thereby minimizing antibiotic resistance concerns.
Claims50
An anti-aging composition comprising a combination of a first therapeutic agent that inhibits mitochondrial biogenesis and targets the large mitochondrial ribosome, a second therapeutic agent that inhibits mitochondrial biogenesis and targets the small mitochondrial ribosome, and a third therapeutic agent that induces mitochondrial oxidative stress.
A method for treating the effects of aging, the method comprising administering to a patient in need thereof an effective amount of a first therapeutic agent that inhibits mitochondrial biogenesis and targets the large mitochondrial ribosome, administering an effective amount of a second therapeutic agent that inhibits mitochondrial biogenesis and targets the small mitochondrial ribosome, and inducing mitochondrial oxidative stress through either a third therapeutic agent or radiation treatment.
An anti-aging therapeutic method comprising:
- inhibiting mitochondrial biogenesis with a first therapeutic agent that targets the large mitochondrial ribosome,
- inhibiting mitochondrial biogenesis with a second therapeutic agent and targets the small mitochondrial ribosome, and
- inducing mitochondrial oxidative stress with a third therapeutic agent.
A pharmaceutical composition comprising:
- a first therapeutic agent selected from azithromycin and a conjugate of azithromycin and a first fatty acid, a second therapeutic agent selected from doxycycline and a conjugate of doxycycline and a second fatty acid, and a third therapeutic agent selected from Vitamin C, ascorbyl palmitate, and an ascorbate derivative.
A method for preventing or delaying the onset of senescence, the method comprising:
- inhibiting mitochondrial biogenesis with a first therapeutic agent that targets the large mitochondrial ribosome,
- inhibiting mitochondrial biogenesis with a second therapeutic agent and targets the small mitochondrial ribosome, and
- inducing mitochondrial oxidative stress with a third therapeutic agent.
Dependencies are inferred from the claim text.